ArticleBMC infectious diseases2017

Cost-utility analysis of Palivizumab for Respiratory Syncytial Virus infection prophylaxis in preterm infants: update based on the clinical evidence in Spain.

M Sanchez-Luna et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.